Rybelsus: The First Oral GLP-1 for Type 2 Diabetes Control
| Product dosage: 14mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $36.22 | $362.20 (0%) | 🛒 Add to cart |
| 20 | $31.19 | $724.40 $623.79 (14%) | 🛒 Add to cart |
| 30 | $29.51
Best per pill | $1086.60 $885.38 (19%) | 🛒 Add to cart |
| Product dosage: 3mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $25.15 | $251.53 (0%) | 🛒 Add to cart |
| 20 | $21.13 | $503.06 $422.57 (16%) | 🛒 Add to cart |
| 30 | $18.45
Best per pill | $754.59 $553.36 (27%) | 🛒 Add to cart |
| Product dosage: 7mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $33.20 | $332.02 $332.02 (0%) | 🛒 Add to cart |
| 20 | $28.17 | $664.04 $563.42 (15%) | 🛒 Add to cart |
| 30 | $26.83
Best per pill | $996.05 $804.89 (19%) | 🛒 Add to cart |
Synonyms | |||
Rybelsus (semaglutide) is a groundbreaking prescription medication developed for the management of type 2 diabetes in adults. As the first and only glucagon-like peptide-1 (GLF-1) receptor agonist available in tablet form, it offers a convenient alternative to injectable therapies. This medication works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, thereby helping to lower blood glucose levels. It is typically used alongside diet and exercise to improve glycemic control and may also support weight management.
Features
- Active ingredient: Semaglutide
- Drug class: Glucagon-like peptide-1 (GLP-1) receptor agonist
- Administration: Oral tablet
- Available strengths: 3 mg, 7 mg, 14 mg
- Requires gradual dose escalation
- Must be taken on an empty stomach with no more than 4 oz of water
Benefits
- Effectively lowers HbA1c levels for improved long-term glycemic control
- Supports weight loss as a beneficial secondary effect
- Reduces cardiovascular risk in patients with established heart disease
- Offers a non-injectable option for GLP-1 therapy, enhancing adherence
- Once-daily dosing convenience supports routine management
- May help preserve beta-cell function over time
Common use
Rybelsus is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be used as monotherapy or in combination with other antihyperglycemic agents, such as metformin, SGLT2 inhibitors, or insulin, when additional glycemic control is needed. It is particularly suitable for patients who prefer oral administration over injectable GLP-1 agonists but seek similar efficacy profiles.
Dosage and direction
Initiate treatment with 3 mg once daily for 30 days. After 30 days, increase the dose to 7 mg once daily. If additional glycemic control is needed after at least 30 days on 7 mg, the dose may be increased to 14 mg once daily. Take Rybelsus at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water. Do not crush, split, or chew the tablet. Swallow whole.
Precautions
Inform your healthcare provider of any history of pancreatitis, diabetic retinopathy, or renal impairment. Monitor for signs of hypoglycemia, especially when used with insulin or sulfonylureas. Use with caution in patients with gastroparesis. Not recommended for use in patients with severe gastrointestinal disease. Thyroid C-cell tumors have been observed in rodent studies; relevance to humans is unknown. Regular monitoring of blood glucose and HbA1c is advised.
Contraindications
Rybelsus is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with a history of hypersensitivity to semaglutide or any component of the product.
Possible side effects
Common side effects include nausea, vomiting, diarrhea, abdominal pain, and decreased appetite. These are often transient and may diminish over time. Hypoglycemia may occur when used with insulin or sulfonylureas. Other potential side effects include dyspepsia, constipation, and gastritis. Serious but rare side effects include pancreatitis, diabetic retinopathy complications, acute kidney injury, and allergic reactions.
Drug interaction
Rybelsus delays gastric emptying and may impact the absorption of concomitantly administered oral medications. Use caution with drugs requiring rapid gastrointestinal absorption or with a narrow therapeutic index (e.g., warfarin, levothyroxine). Monitor blood glucose and adjust doses of insulin or sulfonylureas to reduce hypoglycemia risk. Concomitant use with other GLP-1 receptor agonists is not recommended.
Missed dose
If a dose is missed, skip the missed dose and take the next dose the following day at the regular time. Do not take two doses on the same day to make up for a missed dose.
Overdose
In the event of overdose, expect prolonged and severe nausea, vomiting, and potentially hypoglycemia. Supportive care is recommended, including hydration and antiemetics if needed. Monitor blood glucose and provide carbohydrate intake or glucagon if hypoglycemia occurs. There is no specific antidote for semaglutide overdose.
Storage
Store Rybelsus tablets in the original blister pack at room temperature (68°F–77°F or 20°C–25°C). Excursions are permitted between 59°F–86°F (15°C–30°C). Keep the tablets in a dry place and protect from moisture. Do not remove from the blister until ready to administer.
Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Do not disregard professional medical advice or delay in seeking it because of something you have read here.
Reviews
Clinical trials and post-marketing data demonstrate that Rybelsus is effective in reducing HbA1c and supporting weight management. Many patients appreciate the convenience of an oral GLP-1 option. Some users report gastrointestinal side effects during the initial titration phase, though these often subside. Adherence to administration instructions is critical for optimal efficacy. Overall, it is considered a valuable addition to type 2 diabetes treatment options.